TORONTO, ONTARIO--(Marketwire - Sept. 6, 2012) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTCBB:FOIFF) announces it has entered into an option agreement to acquire the intellectual property rights to a new diagnostic technology which identifies irritable bowel syndrome (IBS).
Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI
TORONTO, ONTARIO--(Marketwire - Aug. 21, 2012) - Arch Biopartners Inc ("Arch") (CNSX:ACH)(OTCBB:FOIFF) today announced Arch scientists have successfully used magnetic resonance imaging ("MRI") to detect human brain tumour initiating cells in mice using Arch's proprietary cell targeting technology.
Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology
TORONTO, CANADA--(Marketwire - March 15, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada - Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell ("BTIC") targeting technology.